Plus Therapeutics (NASDAQ:PSTV) Given New $57.00 Price Target at Ascendiant Capital Markets

Plus Therapeutics (NASDAQ:PSTV) had its price target cut by investment analysts at Ascendiant Capital Markets from $65.00 to $57.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities analysts also recently commented on PSTV. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $56.40.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock opened at $5.41 on Monday. The company has a fifty day simple moving average of $5.66 and a 200-day simple moving average of $8.61. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The stock has a market cap of $37.24 million, a price-to-earnings ratio of -2.35 and a beta of 1.38.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. On average, analysts forecast that Plus Therapeutics will post -3.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP purchased a new stake in shares of Plus Therapeutics during the third quarter worth about $46,000. Jane Street Group LLC purchased a new stake in Plus Therapeutics in the second quarter valued at approximately $41,000. Scientech Research LLC purchased a new stake in Plus Therapeutics in the third quarter valued at approximately $100,000. XTX Topco Ltd purchased a new stake in Plus Therapeutics in the fourth quarter valued at approximately $127,000. Finally, State Street Corp grew its holdings in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the period. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.